Purple Biotech Valuation
| PPBT Stock | USD 6.57 1.83 21.79% |
At this time, the company appears to be undervalued. Purple Biotech holds a recent Real Value of $7.11 per share. The prevailing price of the company is $6.57. Our model determines the value of Purple Biotech from analyzing the company fundamentals such as Shares Owned By Institutions of 9.33 %, return on equity of -0.45, and Shares Outstanding of 1.57 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Purple Biotech's valuation include:
Price Book 0.3498 | Enterprise Value 5 M | Enterprise Value Ebitda (0.15) | Price Sales 58.0756 | Trailing PE 0.0811 |
Undervalued
Today
Please note that Purple Biotech's price fluctuation is dangerous at this time. Calculation of the real value of Purple Biotech is based on 3 months time horizon. Increasing Purple Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Purple Biotech's intrinsic value may or may not be the same as its current market price of 6.57, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.57 | Real 7.11 | Target 9.33 | Hype 6.09 | Naive 8.87 |
The intrinsic value of Purple Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Purple Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Purple Biotech helps investors to forecast how Purple stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Purple Biotech more accurately as focusing exclusively on Purple Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Purple Biotech's intrinsic value based on its ongoing forecasts of Purple Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Purple Biotech's closest peers.
Purple Biotech Cash |
|
Purple Valuation Trend
Purple Biotech's real value is important for investors to make better decisions and a more accurate overall view of Purple Biotech's financial worth over time. Using both Purple Biotech's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Purple Biotech Total Value Analysis
Purple Biotech is at this time forecasted to have valuation of 5.04 M with market capitalization of 11.12 M, debt of 351 K, and cash on hands of 36.02 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Purple Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.04 M | 11.12 M | 351 K | 36.02 M |
Purple Biotech Asset Utilization
One of the ways to look at asset utilization of Purple is to check how much profit was generated for every dollar of assets it reports. Purple Biotech holds a negative application of assets of -0.29 pct., losing $0.002925 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Purple Biotech shows how discouraging it operates for each dollar spent on its assets.Purple Biotech Ownership Allocation
The market capitalization of Purple Biotech is $11.12 Million. Roughly 87.81 pct. of Purple Biotech outstanding shares are held by general public with 2.86 % owned by insiders and only 9.33 (%) by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Purple Biotech Profitability Analysis
Net Loss for the year was (19.88 M) with loss before overhead, payroll, taxes, and interest of (120 K).About Purple Biotech Valuation
The stock valuation mechanism determines Purple Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Purple Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Purple Biotech. We calculate exposure to Purple Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Purple Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -196 K | -186.2 K | |
| Pretax Profit Margin | (91.82) | (87.23) | |
| Operating Profit Margin | 102.37 | 107.49 | |
| Net Loss | (0.09) | (0.10) |
Purple Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Purple Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 221.3 M |
Purple Biotech Current Valuation Indicators
Purple Biotech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Purple Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Purple Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Purple Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Purple Biotech's worth.Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.